Faculty

Back to Index
Maria Teresa Ochoa, MD
Associate Professor of Clinical Dermatology
Dermatology
HC4 2000 1450 San Pablo Health Sciences Campus Los Angeles
+1 323 442 6200

Overview

Dr. Ochoa is an Associate Clinical Professor of Dermatology at the Keck School of Medicine USC. She recently joined the Department of Dermatology at Keck Medicine of USC after 10 years of practice at the UCLA Division of Dermatology.

Dr. Ochoa is a member of the American Academy of Dermatology, the Society for Investigative Dermatology and California Dermatologic Society. Dr. Ochoa sees patients in the private practice settings at Keck Medicine of USC – Beverly Hills, and Healthcare Consultation Center II on the USC Health Sciences Campus, and participates in the care of the uninsured at the LAC+USC Medical Center. She serves as the Director of the Hansen’s clinic.

Dr. Ochoa provides dermatology services for the diagnosis and treatment of a broad range of general skin diseases such as acne, eczema, skin cancer and psoriasis, among others. Her clinical and research interest center around infectious diseases of the skin, including the diagnosis and treatment of patients with skin manifestations of HIV, tropical dermatology (skin infectious diseases acquired abroad) and sexually transmitted diseases.

Dr. Ochoa has a special research interest in the immunologic mechanism of the host response in infectious diseases of the skin.

Publications

IL-27 Suppresses Antimicrobial Activity in Human Leprosy. J Invest Dermatol. 2015 Jun 1. View in: PubMed

T lymphocyte density and distribution in human colorectal mucosa, and inefficiency of current cell isolation protocols. PLoS One. 2015; 10(4):e0122723. View in: PubMed

Recognizing and managing the immunologic reactions in leprosy. J Am Acad Dermatol. 2014 Oct; 71(4):795-803. View in: PubMed

Antigen-Presenting Cell Candidates for HIV-1 Transmission in Human Distal Colonic Mucosa Defined by CD207 Dendritic Cells and CD209 Macrophages. AIDS Res Hum Retroviruses. 2014 Mar; 30(3):241-9. View in: PubMed

NOD2 triggers an interleukin-32-dependent human dendritic cell program in leprosy. Nat Med. 2012 Apr; 18(4):555-63. View in: PubMed

Mobile teledermatology: As doctors and patients are increasingly mobile, technology keeps us connected. Skinmed. 2011 Jul-Aug; 9(4):231-8. View in: PubMed

New World cutaneous leishmaniasis: current challenges in diagnosis and parenteral treatment. J Am Acad Dermatol. 2011 Mar; 64(3):587-92. View in: PubMed

Interleukin-4 regulates the expression of CD209 and subsequent uptake of Mycobacterium leprae by Schwann cells in human leprosy. Infect Immun. 2010 Nov; 78(11):4634-43. View in: PubMed

A role for interleukin-5 in promoting increased immunoglobulin M at the site of disease in leprosy. Immunology. 2010 Nov; 131(3):405-14. View in: PubMed

Human immunodeficiency virus and leishmaniasis. J Glob Infect Dis. 2010 Sep; 2(3):248-57. View in: PubMed

Integrated pathways for neutrophil recruitment and inflammation in leprosy. J Infect Dis. 2010 Feb 15; 201(4):558-69. View in: PubMed

Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell Host Microbe. 2009 Oct 22; 6(4):343-53. View in: PubMed

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009 Oct 1; 15(19):6267-76. View in: PubMed

"Dermal dendritic cells" comprise two distinct populations: CD1+ dendritic cells and CD209+ macrophages. J Invest Dermatol. 2008 Sep; 128(9):2225-31. View in: PubMed

Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest. 2008 Aug; 118(8):2917-28. View in: PubMed

LILRA2 activation inhibits dendritic cell differentiation and antigen presentation to T cells. J Immunol. 2007 Dec 15; 179(12):8128-36. View in: PubMed

Activation of human CD4+ T cells by targeting MHC class II epitopes to endosomal compartments using human CD1 tail sequences. Immunology. 2007 Dec; 122(4):522-31. View in: PubMed

Regulation of human T-cell homing receptor expression in cutaneous bacterial infection. Immunology. 2007 Apr; 120(4):518-25. View in: PubMed

Functional characterization of a T-cell receptor BV6+ T-cell clone derived from a leprosy lesion. Immunology. 2007 Mar; 120(3):354-61. View in: PubMed

Macrophages acquire neutrophil granules for antimicrobial activity against intracellular pathogens. J Immunol. 2006 Aug 1; 177(3):1864-71. View in: PubMed

TLR activation of Langerhans cell-like dendritic cells triggers an antiviral immune response. J Immunol. 2006 Jul 1; 177(1):298-305. View in: PubMed

Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006 Mar 24; 311(5768):1770-3. View in: PubMed

Human dendritic cell expression of HLA-DO is subset specific and regulated by maturation. J Immunol. 2006 Mar 15; 176(6):3536-47. View in: PubMed

TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat Med. 2005 Jun; 11(6):653-60. View in: PubMed

Mohs' micrographic surgery of a proliferating trichilemmal tumor in a young black man. Dermatol Surg. 2005 Mar; 31(3):359-63. View in: PubMed

Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. J Clin Invest. 2004 Mar; 113(5):701-8. View in: PubMed

Use of genetic profiling in leprosy to discriminate clinical forms of the disease. Science. 2003 Sep 12; 301(5639):1527-30. View in: PubMed

Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med. 2003 May; 9(5):525-32. View in: PubMed

Expression of Toll-like receptor 2 on human Schwann cells: a mechanism of nerve damage in leprosy. Infect Immun. 2003 Mar; 71(3):1427-33. View in: PubMed

Distribution of Toll-like receptor 1 and Toll-like receptor 2 in human lymphoid tissue. Immunology. 2003 Jan; 108(1):10-5. View in: PubMed

Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002 Aug 1; 169(3):1535-41. View in: PubMed

Signaling lymphocytic activation molecule expression and regulation in human intracellular infection correlate with Th1 cytokine patterns. J Immunol. 2001 Nov 15; 167(10):5719-24. View in: PubMed

Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg. 2001 Mar-Apr; 64(3-4):187-93. View in: PubMed

Induction of direct antimicrobial activity through mammalian toll-like receptors. Science. 2001 Feb 23; 291(5508):1544-7. View in: PubMed

T-cell release of granulysin contributes to host defense in leprosy. Nat Med. 2001 Feb; 7(2):174-9. View in: PubMed

Role of granulysin in immunity to leprosy. Lepr Rev. 2000 Dec; 71 Suppl:S115; discussion S115-6. View in: PubMed

Activation of toll-like receptor 2 on human dendritic cells triggers induction of IL-12, but not IL-10. J Immunol. 2000 Oct 1; 165(7):3804-10. View in: PubMed

Evidence for human CD4+ T cells in the CD1-restricted repertoire: derivation of mycobacteria-reactive T cells from leprosy lesions. J Immunol. 2000 May 1; 164(9):4790-6. View in: PubMed

Positive IgG Western blot for Borrelia burgdorferi in Colombia. Mem Inst Oswaldo Cruz. 1999 Jul-Aug; 94(4):499-503. View in: PubMed

IL-18 promotes type 1 cytokine production from NK cells and T cells in human intracellular infection. J Immunol. 1999 May 15; 162(10):6114-21. View in: PubMed

Mucosal leishmaniasis due to Leishmania (Viannia) panamensis in Colombia: clinical characteristics. Am J Trop Med Hyg. 1998 Jul; 59(1):49-52. View in: PubMed

Treatment of cutaneous leishmaniasis in Colombia with dapsone. Lancet. 1998 Feb 14; 351(9101):498-9. View in: PubMed

Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Infect Immun. 1998 Feb; 66(2):499-504. View in: PubMed

Lepromatous and tuberculoid leprosy: clinical presentation and cytokine responses. Int J Dermatol. 1996 Nov; 35(11):786-90. View in: PubMed

A yeast-derived antigen from Paracoccidioides brasiliensis useful for serologic testing. Sabouraudia. 1985 Feb; 23(1):23-9. View in: PubMed

Powered bySC CTSI